UK Neurology Devices Market Analysis

UK Neurology Device Market Executive Summary

Neurosurgery routinely involves the interpretation of complex brain imaging, and neurosurgeons routinely provide post-procedural care to INR patients. Endovascular and open neurosurgical techniques are performed by hybrid neurosurgeons in many countries outside the United Kingdom. The majority of neurosurgical training in the United Kingdom consists of 8 years of standardized training. Interventional neuroradiological (INR) procedures are a subset of procedures that treat a wide range of neurovascular disorders. The UK Neurointerventional Group (UKNG) is a group of specialists who perform minimally invasive operations on blood vessels in the brain, spine, head, and neck. These neuro-interventional procedures include the treatment of aneurysms, arteriovenous malformations, and mechanical thrombectomy for acute ischaemic stroke. Our neurology specialists now collaborate with neurosurgeons to diagnose and treat complex neurological and neuromuscular diseases such as Parkinson's disease, ALS (Lou Gehrig's disease), and stroke. The National Hospital for Neurology and Neurosurgery (NHNN), Queen Square, is the UK's largest dedicated neurological and neurosurgical hospital. It is affiliated with the National Health Service (NHS) UK and offers comprehensive services for the diagnosis, treatment, and care of all conditions affecting the brain, spinal cord, peripheral nervous system, and muscles.

Since 2017, major clinical trials like REVASCAT, SWIFT PRIME, EXTEND-IA, ESCAPE, and THRACE have confirmed the role of mechanical thrombectomy (MT) in the treatment of ischemic stroke. There is also evidence that patients admitted after hours with other indications for INR procedures, such as aneurysmal subarachnoid haemorrhage, have poorer outcomes. Endovascular therapy is an essential component of modern stroke care. Subarachnoid haemorrhage accounts for 8.9% of the total stroke burden and causes significant disability and mortality. Endovascular coiling for aneurysmal subarachnoid haemorrhage can reduce dependency and death risk. The NHS spends an estimated total of $156.8 million per year to treat aneurysmal subarachnoid haemorrhage, with the average cost per patient being $22,682. The average inpatient cost of endovascular coiling versus neurosurgical clipping to treat aneurysmal subarachnoid haemorrhage is comparable, but the endovascular procedure has a shorter operating time and a shorter length of hospital stay, which may result in financial savings. Indeed, in the context of ischemic stroke, which costs the NHS around $4 Bn per year, the higher treatment costs of stent-retriever thrombectomy were offset by long-term cost savings due to improved patient health status. This resulted in a total savings of $31,258 per patient. Given the potential long-term cost-effectiveness of endovascular procedures, expanding INR capability could be extremely beneficial, especially in publicly funded healthcare systems. Mechanical Thrombectomy (MT) heralds the resolution of pressing issues for neurosurgeons in the treatment of cerebral aneurysms.

Individual nylon or PGLA microfilaments have been overlapped between coil loops in newer devices, forming an intra-aneurysmal surface area for stable scar tissue formation and high thrombogenicity. These coils offer the acute performance of a coil as well as flow reduction across the neck and increased thrombogenicity. These are helpful in Acute Ischemic Stroke, Brain Aneurysm, Deep Brain Stimulation for Movement Disorders, Deep Brain Stimulation for Psychiatric Disorders, Dura Mater Repair, External Drainage & Monitoring, Head & Neck Surgery, Hydrocephalus Shunting, Idiopathic Intracranial Hypertension Shunting, Spinal Cord Stimulation, Subdural Evacuation, Targeted Drug Delivery for Chronic Pain are some of the disorders treated. Balloon Kyphoplasty, Bone Grafting, Intrathecal Baclofen Therapy for Severe Spasticity, Posterior OCT Reconstruction, Vertebroplasty, and Sacroplasty are all options for spinal reconstruction. Neuro-balloon devices provide stability in large and small vessels by applying supple conformity to complex structures. They are ideal for distal access and unique and irregular anatomies, such as bifurcation geometries. Discover dependable coverage that is specifically designed to create stable occlusion across the difficult diameters found in large and small vessels. Occlusion balloons are specially designed with extra softness to conform to asymmetrical, irregular, and complex vasculature geometries for sidewall aneurysms and reliable occlusions.

Access and Distribution, Products for Revascularization of Acute Ischemic Stroke, Aneurysm Treatment, Cranial Repair, Deep Brain Stimulation Systems for Movement Disorders, Deep Brain Stimulation Systems for Psychiatric Disorders, Haemorrhagic Stroke, Laser Ablation Technology Powered Physicians who have received appropriate training in interventional neuro-endovascular techniques use surgical instruments. Devices are designed to be installed by clinical support staff under the supervision of a trained physician. Recovery of an instrument or device from resistance without careful evaluation of the cause using fluoroscopy can result in breakage or damage, so users must be monitored.

Market Dynamics

Market Growth Drivers

The UK neurology market, a global leader in medical technology, provides treatment providers with a variety of neurology medical devices for the treatment of conditions such as chronic pain, epilepsy, and movement disorders. Medical device companies that offer a variety of neurology medical devices, such as spinal cord stimulation devices, implantable pulse generators, and neurostimulation leads, generate the most revenue, indicating high-demand areas. Implantable Pulse Generators (IPGs) are devices that deliver electrical stimulation to specific areas of the body to treat conditions such as chronic pain, movement disorders, and depression. IPGs have recently gained a significant market share due to their effectiveness and specificity of treatment outcomes. Spinal Cord Stimulation (SCS) devices, which are implantable devices that deliver electrical stimulation to the spinal cord to treat chronic pain, have also gained traction. DBS systems are traditionally used devices that deliver electrical stimulation to specific areas of the brain to treat conditions such as Parkinson's disease and dystonia, which have always been sought after and continue to be in demand in the neurology device market.

Market Restraints

Potential complications include proximal emboli of air, foreign material, tissue, or thrombus, hematoma, haemorrhage, infection, ischemia, and thrombus formation. Neurological deficits that could lead to stroke and death, vessel spasm, dissection, perforation, or injury are all things to be concerned about when treatment providers decide to switch from one manufacturer to another. Torquing without restraint or forcing the catheter against resistance has historically resulted in device or vessel damage, leading to stringent policies that discourage switching brands or manufacturers. Structural integrity and/or function, catheter manipulation, and intralumenal devices are high-risk devices that must pass additional regulatory scrutiny.

Competitive Landscape

Key Players

• Johnson and Johnson
• L. Gore & Associates
• Braun Mesungen
• St. Jude Medical
• Integra LifeSciences Holdings
• Boston Scientific
• Stryker Corporation
• Medtronic PLC
• Rapid Medical
• Acandis
• MicroPort Scientific
• Ekso Bionics
• TyroMotion
• FEsia
• ZeroG
• MAG and more

Notable Recent Updates

November 2021 – Government funding announced by the UK. People suffering from neurodegenerative diseases may live longer, healthier lives as a result of innovative new research, thanks to the UK government's commitment to invest $375 Mn over the next five years. At least $50 Mn will be made available for research to aid in the discovery of a cure for Motor Neuron Disease (MND), which affects the brain and nerves and affects 5,000 people in the UK. The entire investment will go toward projects that will improve our understanding of diseases like Pick's Disease, Fronto-temporal dementia, Wernicke-Korsakoff, Parkinson's disease dementia, Lewy Body dementia, Alzheimer's disease, and mild cognitive impairment while searching for new treatments.

Healthcare Policies and Regulatory Landscape

The Medicines and Healthcare products Regulatory Agency (MHRA) regulates the medical device industry in the UK, including neurology medical devices. For the development, testing, and marketing of medical devices, strict guidelines and standards are in place. The UK has a thriving medical device industry, with several companies developing cutting-edge neurology devices for the diagnosis and treatment of a variety of neurological conditions. The UK National Health Service (NHS) buys and uses these devices on a regular basis in its healthcare facilities. Overall, the position of neurology devices in the UK is strong, with a well-regulated industry and high demand in the healthcare sector. Manufacturers and distributors of neurology devices in the UK are subject to a variety of policies and regulations established by MHRA. Device classification, conformity assessment, device registration, technical documentation, post-market surveillance, and adverse event reporting are some of the key policies and requirements. Medical devices are divided into four categories based on their risk level. Neurology devices are typically classified as Class III or Class IIb, requiring more stringent regulations. Manufacturers must ensure that their devices meet the relevant safety, performance, and quality standards and that they have the documentation to back them up. Manufacturers must register their devices with the MHRA before they can be placed on the market, and any adverse events or incidents related to post-market use must also be reported. Other policies and regulations, such as data protection and privacy laws, must be followed in addition to these requirements. The policies and regulations are in place to ensure the safety, quality, and efficacy of neurology medical devices for patients and healthcare providers.

Reimbursement Scenario

The NHS UK reimburses certain neurology medical devices used to diagnose and treat neurological conditions. The National Institute for Health and Care Excellence (NICE), which provides guidance on the use of healthcare technologies in the NHS, determines the coverage and reimbursement of these devices. To be reimbursed by the NHS, a neurology device must meet certain criteria, including being cost-effective, having a positive impact on patient outcomes, and being recommended by NICE. NICE considers a number of factors when determining whether a device is cost-effective, including clinical effectiveness, device cost, and cost savings generated for the NHS. If a neurology device is approved for reimbursement by the NHS, healthcare providers in the NHS can purchase and use it. The exact reimbursement amount for a device, however, may vary depending on the patient's individual circumstances and the NHS organization that provides the treatment.